The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs ...

KRAS突变是NSCLC中除EGFR之外最常见的驱动基因突变，G12C又是KRAS突变NSCLC患者中占比最高的亚型。该人群在现有非靶向治疗方案中的获益有限，存在 ...

Co-opted Pathways Required by Oncogenic KRAS to Sustain Lung Tumorigenesis Oncogenic KRAS relies on additional pathways that are engaged downstream of these effectors or are required indirectly as ...

every aspect of the KRAS pathway, adjacent downstream, and develop a biomarker that could impact account for all of that diversity.” What Genialis did was to train the biomarker on the 1-million ...

EGFR-positive lung cancer is a type of lung cancer with an epidermal growth factor receptor (EGFR) mutation. In the United States, around 10% to 15% of lung cancers are EGFR-positive. Most of these ...